{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:52:24Z","timestamp":1780379544223,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.parkreldis.2015.09.038","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T17:52:15Z","timestamp":1443203535000},"page":"S82-S92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S1","title":["Interventional trials in atypical parkinsonism"],"prefix":"10.1016","volume":"22","author":[{"given":"S.","family":"Eschlb\u00f6ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Krismer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.K.","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.parkreldis.2015.09.038_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of lewy body dementia: a systematic review and meta-analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.parkreldis.2015.09.038_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.wnf.0000183240.47960.f0","article-title":"Working group on atypical parkinsonism of the Austrian Parkinson's society. Placebo-controlled trial of amantadine in multiple-system atrophy","volume":"28","author":"Wenning","year":"2005","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine","volume":"95","author":"Jankovic","year":"1993","journal-title":"Am. J. Med."},{"issue":"13","key":"10.1016\/j.parkreldis.2015.09.038_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.51.1.120","article-title":"A\u00a0double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension","volume":"51","author":"Wright","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0002-9343(99)80246-0","article-title":"Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension","volume":"99","author":"Fouad-Tarazi","year":"1995","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/HYPERTENSIONAHA.114.04225","article-title":"Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure","volume":"64","author":"Ramirez","year":"2014","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.parkreldis.2015.09.038_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1212\/WNL.53.9.2151","article-title":"The treatment of neurogenic orthostatic hypotension with3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial","volume":"53","author":"Freeman","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000083721.49847.D7","article-title":"Norepinephrine precursor therapy in neurogenic orthostatic hypotension","volume":"108","author":"Kaufmann","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.parkreldis.2015.09.038_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1212\/WNL.0000000000000615","article-title":"Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial","volume":"83","author":"Kaufmann","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni","year":"2015","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02291388","article-title":"Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure","volume":"10","author":"van Lieshout","year":"2000","journal-title":"Clin. Auton. Res."},{"issue":"2","key":"10.1016\/j.parkreldis.2015.09.038_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM197907123010202","article-title":"Mineralocorticoid-induced hypertension in patients with orthostatic hypotension","volume":"301","author":"Chobanian","year":"1979","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2015.09.038_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine treatment trial in neurogenic orthostatic hypotension","volume":"63","author":"Singer","year":"2006","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2015.09.038_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/HYPERTENSIONAHA.110.154898","article-title":"Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure","volume":"56","author":"Shibao","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.107.089961","article-title":"Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function","volume":"50","author":"Shibao","year":"2007","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00002826-199502000-00012","article-title":"Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration","volume":"18","author":"Bordet","year":"1995","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.parkreldis.2015.09.038_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/HYPERTENSIONAHA.111.00377","article-title":"Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure","volume":"61","author":"Arnold","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/HYPERTENSIONAHA.114.04116","article-title":"Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension","volume":"64","author":"Okamoto","year":"2014","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.parkreldis.2015.09.038_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp.71.3.371","article-title":"Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension","volume":"71","author":"Hussain","year":"2001","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.parkreldis.2015.09.038_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini","year":"2003","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2015.09.038_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.21501","article-title":"Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study","volume":"22","author":"Holmberg","year":"2007","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","article-title":"Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)","volume":"25","author":"Dodel","year":"2010","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2015.09.038_bib25","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1468-1331.2006.01452.x","article-title":"Placebo-controlled trial of riluzole in multiple system atrophy","volume":"13","author":"Seppi","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"Pt 1","key":"10.1016\/j.parkreldis.2015.09.038_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2015.09.038_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","article-title":"Treatment of multiple system atrophy using intravenous immunoglobulin","volume":"12","author":"Novak","year":"2012","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A\u00a0randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2015.09.038_bib29","first-page":"458","article-title":"A\u00a0randomized clinical trial of lithium in multiple system atrophy","volume":"260","author":"Sacc\u00e0","year":"2013","journal-title":"J.\u00a0Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2015.09.038_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2015.09.038_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","article-title":"Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial","volume":"14","author":"Poewe","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2015.09.038_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0034-1381739","article-title":"Clinical trials: past, current, and future for atypical Parkinsonian syndromes","volume":"34","author":"Tsai","year":"2014","journal-title":"Semin. Neurol."},{"issue":"Pt 6","key":"10.1016\/j.parkreldis.2015.09.038_bib33","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.parkreldis.2015.09.038_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0034-1381736","article-title":"Progressive supranuclear palsy","volume":"34","author":"Globe","year":"2014","journal-title":"Semin. Neurol."},{"issue":"Suppl.\u00a04","key":"10.1016\/j.parkreldis.2015.09.038_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1468-1331.2006.01650.x","article-title":"Clinical value of botulinum toxin in neurological indications","volume":"13","author":"Ward","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2015.09.038_bib36","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1468-1331.2007.01687.x","article-title":"Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy","volume":"14","author":"Poujois","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2015.09.038_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","article-title":"Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy","volume":"57","author":"Litvan","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.09.038_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jalz.2009.04.1231","article-title":"Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis","volume":"6","author":"Liepelt","year":"2010","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.parkreldis.2015.09.038_bib39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.parkreldis.2015.09.038_bib40","first-page":"265","article-title":"Effects of coenzyme Q10 in PSP, a multicenter, randomized, placebo-controlled, double-blind study [abstr]","volume":"29","author":"Apetauerova","year":"2014","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2015.09.038_bib41","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2015.09.038_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A\u00a0phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.038_bib43","article-title":"The PROSPERA study: a randomized, placebo-controlled, single center trial to evaluate the safety and efficacy of rasagiline in progressive supranuclear palsy [abstr]. Jahrestagung der Deutschen Gesellschaft f\u00fcr Neurologie","author":"N\u00fcbling","year":"2013","journal-title":"Dresden"},{"key":"10.1016\/j.parkreldis.2015.09.038_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-12-14","article-title":"Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study","volume":"12","author":"Giordano","year":"2014","journal-title":"J.\u00a0Transl. Med."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015004290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015004290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T16:13:12Z","timestamp":1599581592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015004290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":44,"alternative-id":["S1353802015004290"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.038","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interventional trials in atypical parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}